Skip to main content
S&P 5007,623.68-0.52%DOW52,215.16-1.23%NASDAQ25,955.34-0.21%BTC$80,645.00-0.98%ETH$2,373.55-0.82%GOLD$4,010.00-1.24%OIL$103.44+3.99%
Smart Investors Daily
SID Premium
AC

OTC · ACUT

Accustem Sciences Inc.

Healthcare · Biotechnology

$0.13

Up+$0.00 (+0.00%)

Updated Oct 24, 2026, 5:37 PM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
6.93M
P/E ratio
-1.3
Dividend yield
0.00%
52-week range
— – —
Volume
12.57K
Avg. volume
1.2K

Price performance · ACUT

ACUT price history

1M range · 0 trading sessions · Daily adjusted prices

ACUT does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest ACUT news

The latest Smart Investors Daily articles mentioning ACUT.

Stock researchCompany · Overview

ACUT research

Overview

Company profile and research snapshot.

Company profile

ACCUSTEM SCIENCES INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Jan 8, 2026

AccuStem Sciences Announces StemPrintER Pilot Study with National Surgical Adjuvant Breast and Bowel Project (NSABP)

Initial study will enable further collaboration on the predictive capabilities of StemPrintERPHOENIX, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced the execution of a pilot study agreement with NSABP to evaluate StemPrintER in a subset of patients from the B-32 cohort. This evaluation will enable the two groups to then confirm the predictive capa

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By